Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

Konstantinos Rounis; Dimitrios Makrakis; Chara Papadaki; Alexia Monastirioti; Lambros Vamvakas; Konstantinos Kalbakis; Krystallia Gourlia; Iordanis Xanthopoulos; Ioannis Tsamardinos; Dimitrios Mavroudis; Sofia Agelaki

doi:10.1371/journal.pone.0294382

Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

PLoS One. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382. eCollection 2023.

Authors

Konstantinos Rounis, Dimitrios Makrakis, Chara Papadaki, Alexia Monastirioti, Lambros Vamvakas, Konstantinos Kalbakis, Krystallia Gourlia, Iordanis Xanthopoulos, Ioannis Tsamardinos, Dimitrios Mavroudis, Sofia Agelaki

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0252537.].

Copyright: © 2023 Rounis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication types

Published Erratum